New cancer drug shows potential in patients with BRCA mutations

June 6, 2013, Newcastle University

(Medical Xpress)—A new cancer drug designed to be effective in tumours with faulty BRCA genes has generated impressive responses in an early-stage clinical trial.

The drug, called BMN 673, targets DNA repair in , and is designed specifically to attack tumours that have been left vulnerable by .

A small study involving Newcastle University found the drug was well tolerated by patients and showed 'excellent anti-tumour activity', the team has announced.

The trial results were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago, US, late yesterday. The trial was funded by US firm BioMarin Pharmaceutical and also involved several institutions in the USA.

The trial results covered 70 patients with a range of cancers – including ovarian or peritoneal, and breast. Patients with cancers linked to saw the most substantial improvement.

The researchers used different measures of the drug's effect on tumour instability and breakdown. One was a clinical score called RECIST, which includes a range of measures such as whether visible lesions, or cracks, appear in the walls of tumours after treatment. Some 11 of 25 evaluable ovarian cancer patients with BRCA mutations had a RECIST-positive response to treatment, as did seven of 18 with BRCA mutations. Signs of some were seen in several more patients.

BRCA mutations reduce cells' ability to repair their DNA, and when inherited substantially increase the risk of developing a range of cancers, including breast, ovarian and prostate.

No targeted treatments have yet been approved specifically for use in patients who have inherited BRCA mutations.

BMN 673 – which is yet to be given a trade name – is one of a handful of a family of molecules called PARP inhibitors which are under development for the . BMN 673 is one of the most promising PARP inhibitors currently being tested in clinical trials.

Nicola Curtin, Professor of Experimental Therapeutics at the Northern Insitute for Cancer Research at Newcastle University, said: "PARP inhibitors are an exciting class of drug because they are specifically designed to exploit a malfunction in that is caused by mutations in BRCA genes. BMN 673 is the most potent PARP inhibitor in clinical development. We saw evidence of PARP inhibition in samples from patients on very low doses of BMN 673 and several patients responded well and the drug was well tolerated."

Study researcher Professor Johann de Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research, London, and Honorary Consultant in Medical Oncology at The Royal Marsden, said: "Patients with germline BRCA-associated tumours have no targeted treatment options, and there is a real need for these to be developed. Our promising study showed that BMN 673, a potent member of a family of potential drugs called PARP inhibitors, had excellent anti-tumour activity.

"It's one of a range of new-style cancer therapies that target specific molecular defects in tumours and offer the potential of more personalised treatments to patients, including those with BRCA mutations."

Researchers now plan a larger, Phase 3 clinical trial of BMN 673 to further explore its potential effectiveness.

Explore further: Some patients with incurable tumors and BRCA mutations respond to new two-drug combination

Related Stories

Some patients with incurable tumors and BRCA mutations respond to new two-drug combination

April 7, 2013
A novel combination of two drugs has shown anti-cancer activity in patients who had incurable solid tumors and carried a germline mutation in their BRCA genes, Dana-Farber Cancer Institute researchers are reporting at the ...

PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations

May 15, 2013
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced ...

Olaparib shows promise in treating ovarian cancer, even without BRCA mutations

August 21, 2011
The PARP inhibitor, olaparib, that has shown promise in women with an inherited mutation in their BRCA1 or BRCA2 gene (accounting for about 5-10% of breast and ovarian cancer cases), has, for the first time, been shown to ...

PARP inhibitors may have clinical utility in HER2-positive breast cancers

September 17, 2012
Poly (ADP-Ribose) polymerase (PARP) inhibitors, shown to have clinical activity when used alone in women with familial breast and ovarian cancers linked to BRCA mutations, may be a novel treatment strategy in women with HER2-positive ...

BRCA1 or BRCA2 mutation research may offer treatment option to certain patients

September 20, 2012
(Medical Xpress)—Ongoing research at the Methodist Cancer Center could reveal whether metastatic breast cancer patients with BRCA gene mutations are particularly responsive to a drug regimen that includes Veliparib, an ...

Breakthrough could make 'smart drugs' effective for many cancer patients

June 27, 2011
(Medical Xpress) -- Newcastle and Harvard University reseachers have found that blocking a key component of the DNA repair process could extend the use of a new range of 'smart' cancer drugs called PARP inhibitors.

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.